COBRRA DELIVERS THE FIRST HEAD-TO-HEAD DOAC COMPARISON IN VTE

For over a decade, the question of whether to use apixaban or rivaroxaban for treating acute venous thromboembolism (VTE) has remained. Both are considered efficacious.COBRA Trial | N Engl J Med